While the diagnostic utility of EGFR or EGFRvIII as biomarkers for GBM remains contentious, various therapies targeting EGFR and EGFRvIII have been explored, including tyrosine kinase inhibitors (TKIs), monoclonal antibodies, peptide vaccines, and chimeric antigen receptor T-cells [64]. This evidence concerns the gene EGFR and glioblastoma.